The Prevalence of Barrett's Esophagus in Patients with *
巴雷特食管在以下患者中的患病率*
基本信息
- 批准号:6804636
- 负责人:
- 金额:$ 7.55万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-09-01 至 2005-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant):
The incidence of esophageal adenocarcinoma arising from Barrett's metaplasia has increased by 350% since 1970 and at the time of presentation, 50% of patients will have advanced disease with virtually no chance for cure. The prognosis for esophageal adenocarcinoma arising from Barrett's metaplasia is poor: The overall 5-year survival rate is less than 10%. Patients with classic and chronic symptoms of gastroesophageal reflux disease (GERD) undergo endoscopic screening for Barrett's metaplasia. Several retrospective studies have demonstrated an earlier stage of diagnosis and a marked improvement in survival of patients with cancers detected by routine endoscopic surveillance for Barrett's esophagus. In spite of these efforts, the majority of patients who develop esophageal adenocarcinoma are unaware of the presence of Barrett's metaplasia prior to cancer diagnosis. In addition, a large proportion of these patients have never reported symptoms of GERD. These findings suggest that the majority of patients who are at highest risk for the development of esophageal adenocarcinoma are never screened for Barrett's metaplasia. Some investigators have suggested that patients who develop esophageal cancer may not have typical GERD symptoms and therefore are not identified for endoscopic screening. As a result, occult disease progression occurs and advanced cancer is present at the time of diagnosis.
Substantial published data support a causal relation between complicated GERD (esophagitis and Barrett's metaplasia) and extraesophageal reflux symptoms. The prevalence of GERD-related esophageal injury in patients with isolated extraesophageal symptoms (i.e., no heartburn or regurgitation) is unknown.
The primary aim of this study is to establish that patients with symptoms of extraesophageal reflux who are referred to an otolaryngology clinic have a prevalence of Barrett's metaplasia equivalent to that of a population with GERD symptoms. We will compare the prevalence of biopsy proven Barrett's metaplasia in patients with extraesophageal reflux symptoms with patients who have GERD symptoms and those who do not have GERD symptoms. The two comparison groups will be prospectively accrued through the Clinical Outcomes Research Initiative (CORI) endoscopic database at Oregon Health and Science University and the Portland VA Medical Center.
This pilot study will provide needed data to improve risk stratification for esophageal adenocarcinoma and potentially modify the inclusion criteria for routine Barrett's screening. In addition, this study will enhance our understanding of the natural history of esophageal injury in patients with extraesophageal reflux and raise awareness of non-GERD risk factors.
描述(由申请人提供):
自1970年以来,由Barrett化生引起的食管腺癌的发病率增加了350%,在出现时,50%的患者将患有晚期疾病,几乎没有治愈的机会。Barrett化生引起的食管腺癌预后差:总的5年生存率低于10%。胃食管反流病(GERD)的典型和慢性症状的患者接受Barrett化生的内镜筛查。几项回顾性研究表明,通过常规内镜监测发现的巴雷特食管癌症患者的早期诊断和生存率显着提高。尽管有这些努力,大多数食管腺癌患者在癌症诊断前并不知道存在巴雷特化生。此外,这些患者中有很大一部分从未报告过GERD症状。这些发现表明,大多数食管腺癌发生风险最高的患者从未接受过Barrett化生筛查。一些研究者认为,食管癌患者可能没有典型的GERD症状,因此不能进行内镜筛查。因此,发生隐匿性疾病进展,并且在诊断时存在晚期癌症。
大量已发表的数据支持复杂性GERD(食管炎和Barrett化生)与食管外反流症状之间的因果关系。在有孤立性食管外症状的患者中GERD相关食管损伤的患病率(即,无胃灼热或反流)。
本研究的主要目的是确定有食管外反流症状的患者转诊至耳鼻喉科诊所,其Barrett化生的患病率与有GERD症状的人群相当。我们将比较食管外反流症状患者与有GERD症状和无GERD症状患者活检证实的Barrett化生的患病率。两个对照组将通过俄勒冈州健康与科学大学和波特兰VA医学中心的临床结局研究计划(科里)内窥镜数据库进行前瞻性累积。
这项初步研究将提供所需的数据,以改善食管腺癌的风险分层,并可能修改常规巴雷特筛查的入选标准。此外,这项研究将提高我们对食管外反流患者食管损伤自然史的理解,并提高对非GERD危险因素的认识。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Unsedated small-caliber upper endoscopy: an emerging diagnostic and therapeutic technology.
无镇静小口径上消化道内窥镜检查:一种新兴的诊断和治疗技术。
- DOI:10.1177/155335060601300106
- 发表时间:2006
- 期刊:
- 影响因子:1.5
- 作者:Kim,CharlesY;O'Rourke,RobertW;Chang,EugeneY;Jobe,BlairA
- 通讯作者:Jobe,BlairA
EUS characteristics of Nissen fundoplication: normal appearance and mechanisms of failure.
Nissen 胃底折叠术的 EUS 特征:正常外观和失败机制。
- DOI:10.1016/j.gie.2005.08.044
- 发表时间:2006
- 期刊:
- 影响因子:0
- 作者:Gopal,DeepakV;Chang,EugeneY;Kim,CharlesY;Sandone,Corinne;Pfau,PatrickR;Frick,TerrenceJ;Hunter,JohnG;Kahrilas,PeterJ;Jobe,BlairA
- 通讯作者:Jobe,BlairA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BLAIR Anderson JOBE其他文献
BLAIR Anderson JOBE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BLAIR Anderson JOBE', 18)}}的其他基金
Clinical Risk Factors for Barretts Esophagus in a Primary Care Setting
初级保健机构中巴雷特食管的临床危险因素
- 批准号:
7456008 - 财政年份:2008
- 资助金额:
$ 7.55万 - 项目类别:
Clinical Risk Factors for Barretts Esophagus in a Primary Care Setting
初级保健机构中巴雷特食管的临床危险因素
- 批准号:
7683278 - 财政年份:2008
- 资助金额:
$ 7.55万 - 项目类别:
SCREENING FOR BARRETT'S ESOPHAGUS IN OTOLARYNGOLOGY PATIENTS
耳鼻喉科患者巴雷特食管筛查
- 批准号:
7206629 - 财政年份:2005
- 资助金额:
$ 7.55万 - 项目类别:
Screening for Barrett's in Otolaryngology Patients
耳鼻喉科患者的巴雷特氏病筛查
- 批准号:
6712315 - 财政年份:2004
- 资助金额:
$ 7.55万 - 项目类别:
Screening for Barrett's in Otolaryngology Patients
耳鼻喉科患者的巴雷特氏病筛查
- 批准号:
7724808 - 财政年份:2004
- 资助金额:
$ 7.55万 - 项目类别:
Screening for Barrett's in Otolaryngology Patients
耳鼻喉科患者的巴雷特氏病筛查
- 批准号:
6987153 - 财政年份:2004
- 资助金额:
$ 7.55万 - 项目类别:
Screening for Barrett's in Otolaryngology Patients
耳鼻喉科患者的巴雷特氏病筛查
- 批准号:
6846552 - 财政年份:2004
- 资助金额:
$ 7.55万 - 项目类别:
The Prevalence of Barrett's Esophagus in Patients with *
巴雷特食管在以下患者中的患病率*
- 批准号:
6743029 - 财政年份:2003
- 资助金额:
$ 7.55万 - 项目类别:
相似国自然基金
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
- 批准号:82372007
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
- 批准号:
10751872 - 财政年份:2024
- 资助金额:
$ 7.55万 - 项目类别:
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
- 批准号:
10638347 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Risk stratifying indeterminate pulmonary nodules with jointly learned features from longitudinal radiologic and clinical big data
利用纵向放射学和临床大数据共同学习的特征对不确定的肺结节进行风险分层
- 批准号:
10678264 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
Console Upgrade for 4.7T PET-MRI Preclinical Scanner
4.7T PET-MRI 临床前扫描仪控制台升级
- 批准号:
10630520 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
The role of focal adhesion kinase in therapy resistant prostate tumors
粘着斑激酶在治疗耐药性前列腺肿瘤中的作用
- 批准号:
10638034 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别:
WASHINGTON UNIVERSITY HUMAN TUMOR ATLAS RESEARCH CENTER
华盛顿大学人类肿瘤阿特拉斯研究中心
- 批准号:
10819927 - 财政年份:2023
- 资助金额:
$ 7.55万 - 项目类别: